Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hanie Abdel Masih

Internal Medicine Rockingham, NC Doctor of Osteopathy

NPI 1003202458 CMS profile 5697545

921 S Long Dr Ste 101, Rockingham, NC 28379

Open in the dashboard

General payments

$4,957

295 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hanie Abdel Masih of Rockingham, NC is reported in the CMS Open Payments database as having received $4,957 across 295 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $446 17
2024 General $741 32
2023 General $951 43
2022 General $402 25
2021 General $873 60
2020 General $1,095 75
2019 General $448 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hanie Abdel Masih
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hanie Abdel Masih were reported at $446. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hanie Abdel Masih Internal Medicine median Middle half National median
2019 $448 $159 $48–$570 $163
2020 $1,095 $119 $33–$402 $114
2021 $873 $135 $37–$521 $132
2022 $402 $141 $42–$496 $149
2023 $951 $149 $45–$519 $160
2024 $741 $154 $47–$537 $164
2025 $446 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $967 41 payments
  2. Novo Nordisk Inc $885 71 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $637 36 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $435 25 payments
  5. Lilly USA, LLC $221 16 payments
  6. Pfizer Inc. $204 12 payments
  7. Exact Sciences Corporation $189 9 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $185 12 payments
  9. GlaxoSmithKline, LLC. $138 9 payments
  10. Merck Sharp & Dohme Corporation $127 9 payments
  11. Other $970 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,927 294 payments
  2. Education $30 1 payment
Products named General payments · program years 2019–2025
  1. Kerendia $637 36 payments
  2. FARXIGA $572 22 payments
  3. Ozempic $513 49 payments
  4. RYBELSUS $349 25 payments
  5. JARDIANCE Diabetes $301 16 payments
  6. AIRSUPRA $205 10 payments
  7. Cologuard Collection Kit $189 9 payments
  8. BREZTRI $175 3 payments
  9. JARDIANCE Diabetes $129 9 payments
  10. STEGLATRO $127 9 payments
  11. Other $2,773 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

5,022

Median for Family Practice: 1,826

Drug cost

$475,717

Median for Family Practice: $120,094

Branded share of claims

24.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 57 $78,079
Eliquis Apixaban Brand 60 $54,519
Jardiance Empagliflozin Brand 35 $48,006
Januvia Sitagliptin Phosphate Brand 43 $41,962
Trulicity Dulaglutide Brand 32 $32,739
Entresto Sacubitril/Valsartan Brand 17 $28,566
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $25,492
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 37 $23,026
Farxiga Dapagliflozin Propanediol Brand 16 $20,210
Xarelto Rivaroxaban Brand 14 $18,918

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$20,645

Medicare's payments for the services billed

Medicare patients

85

Average age 70

Services billed

324

41 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 27%
Chronic kidney disease 25%
Heart failure 20%
Ischemic heart disease 19%
Cancer 19%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $129
$129 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $123
$123 16 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $90
$90 — —
Xelstrym
  • Noven Therapeutics, LLC $24
$24 — —
Veozah
  • Astellas Pharma US Inc $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

295 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record